Deciphera Pharmaceuticals, Inc. (DCPH) Covered Calls

You can sell covered calls on Deciphera Pharmaceuticals, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DCPH (prices last updated Thu 4:16 PM ET):

Deciphera Pharmaceuticals, Inc. (DCPH) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
25.38 +0.02 25.36 25.38 1.4M - 2.0
Covered Calls For Deciphera Pharmaceuticals, Inc. (DCPH)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
May 17 25 0.30 25.08 -0.3% -6.8%
Jun 21 25 0.40 24.98 0.1% 0.7%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.